We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Geistlich News

29. September 2021

Innovation Award 2021: Recognition Award for Geistlich Pharma

Geistlich Pharma wins the Innovation Recognition Award for the medical device Geistlich Derma-Gide®. Launched on the US market in 2019, the product particularly supports the healing process of foot ulcers that occur as a late consequence of diabetes. The novel wound matrix is an innovation that was developed 100% in Central Switzerland, is produced here.

Around 425 million people worldwide suffer from diabetes, and in Switzerland it is estimated that a good 500,000 patients are affected. Chronic wounds in the foot and lower leg area are a particularly dreaded late consequence of this disease. Around one in three patients develops a foot ulcer in the course of their lives. A third of these do not heal with conventional standard therapies.  

The alternative to amputation

All too often, a foot has to be amputated. Geistlich Derma-Gide® helps to avoid this radical intervention with efficient wound healing. Niklaus Stiefel, Principal Scientist, Product Development at Geistlich, sums up the product's mode of action as follows: "The key to success lies in obtaining the best from two raw materials and in close cooperation with clinicians. The result: Geistlich Derma-Gide® mimics the skin, helps close wounds and can prevent amputations." 

From US approval to recommended use  

Geistlich Derma-Gide® is currently approved and launched in the USA. Like every Geistlich Pharma development, the new wound matrix was also created under one Central Swiss roof. In 2017, the product gained FDA approval in the USA (U.S. Food and Drug Administration. In 2018, the pre-launch (pilot phase) confirmed the clinical performance, plus the achievements of ease of use. Finally, in 2019, the launch took place in the U.S. market. Since then, Geistlich Derma-Gide® has been listed for use and thus recommended by numerous American health insurers. Geistlich Pharma is delighted to receive the recognition award from the Central Switzerland Chamber of Commerce and Industry (ihz).